Under this new framework, regulators may be able to approve the treatment even when large patient populations don’t exist, if researchers can clearly show:
- How a disease works at the genetic, cellular, or molecular level;
- How a treatment addresses that mechanism, and
- Improvements that would not have been seen in patients without treatment.
This shift towards evaluating potential therapies based on how well they address specific mechanisms could speed up the development of rare disease treatments. It also means that it’s more important than ever to make sure patients and healthcare providers have a clear understanding of the science behind the disease and treatment so that they can make confident, informed decisions about their care.
Our other ideas worth exploring
On journey mapping
Moving beyond customer-centricity theatre. An in-depth breakdown of journey maps and how to use them correctly.
The case for early investment in rare disease state education
An examination of reasons why disease state education for rare diseases helps patients better navigate their journey and complex decisions.
Bedside Manners: How a family doctor approaches patient education
An interview with Dr. Heather Senn, a family doctor, about her philosophies and strategies around patient education.